Purpose: To describe a novel case of optic disc edema in the setting of VEXAS syndrome. Methods: A single case is evaluated. Results: A 77-year-old man presented with optic disc edema and hemorrhage and was initially diagnosed with relapsing chondritis. Subsequently, he was diagnosed with VEXAS syndrome, which resolved with an increase in immunosuppressive treatment. Conclusions: Patients with VEXAS syndrome may present with a spectrum of ocular manifestations, including optic disc edema.
BeckDBFerradaMASikoraKA, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383(27):2628-2638. doi:10.1056/NEJMoa2026834
2.
KosterMJWarringtonKJ. VEXAS within the spectrum of rheumatologic disease. Semin Hematol. 2021;58(4):218-225. doi:10.1053/j.seminhematol.2021.10.002
FerradaMASikoraKALuoY, et al. Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol. 2021;73(10):1886-1895. doi:10.1002/art.41743
5.
CardoneanuARezusIIBurluiAM, et al. Autoimmunity and autoinflammation: relapsing polychondritis and VEXAS syndrome challenge. Int J Mol Sci. 2024;25(4):2261. doi:10.3390/ijms25042261
6.
FanloPRománML de SFonollosaAIlarramendiJHerasHGraysonP. Episcleritis and periorbital edema secondary to VEXAS syndrome. Arch Soc Esp Oftalmol (Engl Ed). 2023;98(10):607-610. doi:10.1016/j.oftale.2023.07.004
7.
LokhandeAJarmaleSVaishnavYJSchaeferJ. An orbital manifestation of VEXAS syndrome. Ophthalmic Plast Reconstr Surg. 2023;39(6):e194-e197. doi:10.1097/IOP.0000000000002450
8.
AbumanhalMLeibovitchIZisapelMEviatarTEdelYBen CnaanR. Ocular and orbital manifestations in VEXAS syndrome. Eye. 2024;38(9):1748-1754. doi:10.1038/s41433-024-03014-3
9.
Georgin-LavialleSTerrierBGuedonAF, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022;186(3):564-574. doi:10.1111/bjd.20805
10.
TakahashiNTakeichiTNishidaT, et al. Extensive multiple organ involvement in VEXAS syndrome. Arthritis Rheumatol. 2021;73(10):1896-1897. doi:10.1002/art.41775
11.
BellaghaRDhaouadiTRiahiA, et al. A regression predictive model for QuantiFERON-TB Gold Plus® indeterminate results in immunosuppressed patients. SAGE Open Med. 2024;12:20503121241279116. doi:10.1177/20503121241279116
12.
HelwigUMüllerMHedderichJSchreiberS. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. J Crohns Colitis. 2012;6(4):419-424. doi:10.1016/j.crohns.2011.09.011
